23andMe Holding Co. (OQ:ME)
Business Focus: Medical & Diagnostic Laboratories
| Sector: Healthcare | Industry: Healthcare Facilities & Services |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 349 Oyster Point Boulevard SOUTH SAN FRANCISCO CA 94080 |
| Tel: | N/A |
| Website: | https://investors.23andme.com |
| IR: | See website |
| Key People | ||
| Anne Wojcicki Chief Executive Officer, Director | Paul Johnson Chief Operating Officer - Consumer | Steve Schoch Chief Accounting Officer |
| Kathy L. Hibbs Chief Administrative Officer, Company Secretary | Kenneth J. Hillan Chief Therapeutics Officer | |
| Business Overview |
| 23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients' lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates. |
| Financial Overview |
| For the fiscal year ended 31 March 2023, 23andMe Holding Co. revenues increased 10% to $299.5M. Net loss increased 43% to $311.7M. Revenues reflect Telehealth segment increase from $19.2M to $44.7M, Research services segment increase of 5% to $52.4M, United States segment increase of 13% to $217.2M, United Kingdom segment increase of 8% to $63M. |
| Employees: | 769 as of Mar 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $558.72M as of Mar 31, 2023 |
| Annual revenue (TTM): | $299.49M as of Mar 31, 2023 |
| EBITDA (TTM): | -$276.74M as of Mar 31, 2023 |
| Net annual income (TTM): | -$311.66M as of Mar 31, 2023 |
| Free cash flow (TTM): | -$176.70M as of Mar 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 461,255,005 as of May 18, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2023 INK Research Corp. All rights reserved.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.